Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist.

As a physician in a large WHO collaborating center in Zagreb, Croatia, Miro was the clinical investigator in several Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. He founded Ergomed in 1997, introducing the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro co-founded PrimeVigilance in 2008, now a leading specialist provider of pharmacovigilance services to the pharmaceutical industry and winner of the Queen’s Award for Enterprise in both 2014 and 2019. In 2014, Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange and has since completed several acquisitions and secondary offerings.

Miro brings his in-depth experience in clinical development and operational execution in drug development to the Board, as well as detailed knowledge of the Group and its operations.

Miro is Chair of Ergomed’s Nomination Committee.